e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
Rhea-AI Summary
e-therapeutics has announced plans to present new preclinical data for ETX-148 at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2025. The presentation will showcase the efficacy and safety results of ETX-148 in murine models of haemophilia A and B. ETX-148, which is being developed for treating bleeding disorders, is currently in IND-enabling studies, with an IND submission planned for 2026.
The oral presentation, numbered OR10, will take place during the SLAM session on February 7th, 2025, at EAHAD 2025, which runs from February 4th to 7th.
Positive
- ETX-148 is progressing through IND-enabling studies
- Company has preclinical data ready for presentation at major industry conference
Negative
- IND submission not expected until 2026, indicating lengthy development timeline ahead
LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.
Presentation Details
Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B
Format: Oral Presentation
Presentation Number: OR10
Date: 7th February 2025
Session: SLAM
About e-therapeutics plc
e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic™, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.
Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, heart failure, and cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing its GalOmic™ therapies towards the clinic with its most developed assets, ETX-312 for MASH, ETX-148 for bleeding disorders, and ETX-407 for dry AMD, at the IND-enabling stage.
Press Contact
press@etherapeutics.co.uk
Investor Relations Contact
investorrelations@etherapeutics.co.uk
FAQ
What is the current development stage of ETX-148 (ETXPF)?
What conditions is ETX-148 (ETXPF) being developed to treat?
When will e-therapeutics present ETX-148 preclinical data at EAHAD 2025?
What type of data will be presented for ETX-148 (ETXPF) at EAHAD 2025?
